Saturday, 10 October 2026European Markets

PARROT Stock Bullish By 16% In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of PARROT (CAC 40: PARRO.PA) jumped by a staggering 16.35% in 5 sessions from $4.71 to $5.48 at 16:11 EST on Tuesday, after two sequential sessions in a row of gains. CAC 40 is sliding 0.07% to $7,132.35, following the last session's downward trend.

About PARROT

Parrot S.A. provides commercial drones, covering equipment, and software and services in France and internationally. It also offers Pix4Dmapper, a drone modelling software; data sensors for precision farming; and mobile, desktop, cloud, SaaS, and business solutions. In addition, the company offers drone-based vine monitoring solutions; and car kit, audio, drone disco, AR drone, swing, mini drones, and connected garden solutions. It serves agriculture; 3D mapping, surveying, and inspection; and defense and security markets. The company was founded in 1994 and is headquartered in Paris, France.

Earnings Per Share

As for profitability, PARROT has a trailing twelve months EPS of $-0.06.

More news about PARROT (PARRO.PA).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,366 source documents archived
Query this data → isubstrate.com